非单胺靶标抗抑郁药研究进展

Advance in research of non-monoamine-targeted antidepressants

目前临床上所使用的抗抑郁药绝大多数以5-羟色胺、去甲肾上腺素和多巴胺等单胺受体为靶标。这些单胺靶标抗抑郁药起效慢、疗效不佳、易复发,远不能满足临床需求。抑郁症的病理学研究表明,一些非单胺受体也参与其中并起重要作用,以非单胺受体为靶标的抗抑郁药已成为抗抑郁药研究的热点。非单胺靶标抗抑郁药在体内外实验中有良好的活性,有些已经进入临床研究,临床研究表明其中某些抗抑郁药起效较快。文中综述非单胺靶标抗抑郁药的研究进展。

Most currently available antidepressants in clinic are based upon monoamine targets. The targets include 5-HT receptor, NE receptor and DA receptor. However, these antidepressants are far from fulfilling our expectations in terms of efficacy, onset of action and side effects. The increasing understanding of the molecular mechanisms of depression shows that many non-monoamine targets are also involved in depression too. The antidepressants of non-monoamine targets have become the hot research of antidepressants, and there are increasing reports of these antidepressants. The non-monoamine-targeted antidepressants exhibit high activity in receptor binding and animal models of depression; some of them are under clinical trials. The clinical trials indicate that several non-monoamine-targeted antidepressants have a faster onset of antidepressant action. In the article, we reviewed the advance in the research of non-monoamine-targeted antidepressants.